| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b9ed41ec71e1e3d004841f54c9eabd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e534a7b761a2f8994a2ce6ea5cc353ce |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 |
| filingDate |
2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98be46f91105715bac396f17d32f53b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9b155e0de8e0c6fd7a45603896b942d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc547396b3aafd81a849b2c7005258e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_728ee638c6356c7c918da8b5dd824618
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c88082659d2890b258c11cb88520c3d |
| publicationDate |
2022-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115109069-A |
| titleOfInvention |
Stereospecific synthesis of acetyldihydroartemisinin and its anti-atherosclerosis application |
| abstract |
The invention discloses a stereospecific synthesis method of acetyldihydroartemisinin and a new application of acetyldihydroartemisinin in the cardiovascular field. The acetyldihydroartemisinin molecular formula is C 17 H 26 O 6 , the molecular weight is 326.39, and there are stereoisomers, namely α-acetyldihydroartemisinin (structural formula shown in formula I) and β-acetyldihydroartemisinin. Hydroartemisinin (structural formula is shown in formula II). The new use is the application of acetyldihydroartemisinin in the preparation of products for preventing and/or treating atherosclerosis-related diseases. Pharmacodynamic studies in ApoE‑/‑mice show that the combination of acetyldihydroartemisinin and low-dose atorvastatin can inhibit the formation of aortic plaques in mice. Vastatin is equivalent. The compound medicine is mainly used for the prevention and treatment of atherosclerosis patients and potential patients. |
| priorityDate |
2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |